Abstract
• ■ Response rate: 50-65% (87.5% within 2 months). • ■ Relapse in 80% after down titration, 80% response again on up titration. • ■ Relapse after end of treatment: 55%, usually transient.
| Original language | English |
|---|---|
| Pages (from-to) | S160 |
| Journal | Journal of Hepatology |
| Volume | 11 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - 1990 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver